Patients with atrial fibrillation who suffer a stroke while on NOAC therapy remain at high risk for recurrent ischemic stroke and bleeding, highlighting a need for improved secondary prevention strategies.
Patients suffering a stroke despite being on nonvitamin K antagonist oral anticoagulant therapy are at high risk of recurrent ischemic stroke and bleeding. In these patients, further research is needed to improve secondary prevention by investigating the mechanisms of recurrent ischemic stroke and bleeding.
Paciaroni et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: